PAREXEL NAMES RONALD E. KEENEY, M.D., AS HEAD OF PEDIATRIC CLINICAL RESEARCH
BOSTON, MA, January 10, 2000 — PAREXEL International Corporation (Nasdaq: PRXL) recently announced the appointment of Ronald E. Keeney, M.D. as Head of Pediatric Clinical Research, reporting to Jonathan M. Fishbein, M.D., Vice President, North American Medical Services. Dr. Keeney is responsible for providing medical leadership to Pediatric clinical projects and will develop and oversee collaborative relationships with children's academic research centers. In addition, Dr. Keeney will provide medical leadership for infectious disease clinical trials.
Dr. Keeney also holds the appointment of Clinical Professor of Pediatrics at University of North Carolina and until joining PAREXEL, was Director of Clinical Research at the WakeMed Clinical Research Institute. He has specialized in infectious disease drug development during much of his career. For ten years, he held numerous positions at Glaxo (now GlaxoWellcome, Inc.), including Director of Infectious Disease Clinical Research, Vice President of Medical Affairs, and Director of Clinical Development. Prior to Glaxo, Dr. Keeney was Associate Director of Virology Clinical Research at Burroughs Wellcome Co.
A native of Bourbon, Missouri, Dr. Keeney earned his B.A. in Biology, Magna cum laude, from Southeast Missouri State College (now University). As a graduate of the University of Missouri School of Medicine, he completed his residency in Pediatrics at the University of Michigan C. S. Mott Children's Hospital and a Pediatrics Infectious Disease Fellowship at Washington University St. Louis Children's Hospital (St. Louis).
Dr. Keeney is a member of the editorial board of the book Applied Clinical Trials: The Global Guide to Clinical Trials Management and the journal, Applied Clinical Trials. His professional memberships include the American Medical Association, the International Society for Antiviral Research, the Drug Information Association, and the Association of Clinical Research Professionals. He was founding president and is a member of the American Academy of Pharmaceutical Physicians and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians, UK.
This release contains "forward-looking" statements regarding future results and events, including statements regarding expected future growth and customer demand. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Factors that might cause such a difference include, but are not limited, to risks associated with: loss or delay of large contracts; the Company's dependence on certain industries and clients; the Company's ability to manage growth and its ability to attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses; government regulation of certain industries and clients; competition and consolidation within the industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. These factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 1999.
PAREXEL is a leading contract research, medical marketing, consulting services organization providing a broad range of knowledge-based outsourcing to the worldwide pharmaceutical, biotechnology, and medical device industries and to the academic community. Over the past fifteen years, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training, publishing and other drug development consulting services. PAREXEL is the first major CRO to develop a pediatric clinical research initiative to respond to the recently enacted FDA Modernization Act and the Final Pediatric Rule. Headquartered near Boston, MA, PAREXEL has approximately 4,400 employees in 46 locations throughout 29 countries around the world.